Perform Another (Advanced) Search

1.  Study Posting (5446) Trial #158398, Polycystic Ovarian Syndrome, Hershey, PA
...inhibitor (letrozole) is more likely to result in live birth than ovulation induction with a selective estrogen receptor modulator (clomiphene citrate) in infertile women with PCOS. A safety hypothesis will also be ...
View Page

2.  Newly Approved Drug Therapies (964) Evista (raloxifene hydrochloride), Eli Lilly,
...women General Information Evista (raloxifene hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of ...
View Page

3.  Newly Approved Drug Therapies (354) Evista (raloxifene hydrochloride), Eli Lilly,
...of osteoporosis in postmenopausal women. Evista, the first in a class of new drugs called selective estrogen receptor modulators (SERMs) to be approved by the FDA for marketing for the prevention of ...
View Page

4.  Study Posting (4694) Trial #83471, Breast Cancer, Poughkeepsie, NY
...Breast implants. • Current therapy with any hormonal agents such as raloxifene (Evista), tamoxifen, or other selective estrogen receptor modulators (SERMs). May become eligible if these medications are discontinued before randomization. • Pregnancy or ...
View Page

5.  Study Posting (1918) Trial #159183, Breast Cancer, Savannah, GA
...trastuzumab (herceptin) allowed • Chemotherapy • See Disease Characteristics Endocrine therapy • More than 1 year since prior selective estrogen-receptor modulators (SERMs) before the breast cancer diagnosis • No hormone replacement therapy during the year ...
View Page

6.  Study Posting (1918) Trial #160124, Breast Cancer, Savannah, GA
...has a recurrence score of 11-25 • Patients who develop breast cancer while receiving a selective estrogen-receptor modulator (SERM) (e.g., tamoxifen, toremifene, or raloxifene) or an aromatase inhibitor (e.g ...
View Page

7.  Study Posting (1918) Trial #160125, Breast Cancer, Savannah, GA
...pills, ovarian hormone replacement therapy) • No concurrent hormonal agent, such as raloxifene, tamoxifen, or other selective estrogen-receptor modulator (SERM), either for osteoporosis or breast cancer prevention • No major surgical procedures (other ...
View Page

8.  Study Posting (1918) Trial #161384, Breast Cancer, Savannah, GA
...therapy, including any of the following: • Hormonal agent for management of osteoporosis (e.g., raloxifene) • Selective estrogen receptor modulators (e.g., raloxifene) • Sex hormonal therapy (e.g., estrogen- or progesterone-replacement therapy ...
View Page